A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD
NCT07093528
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
To evaluate the effect of CS reducer implantation in patients with HFPEF and CMD on myocardial ischemia, measured by stress myocardial perfusion using cardiovascular magnetic resonance (CMR)
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Heart Failure With Preserved Ejection Fraction
- Coronary Microvascular Dysfunction
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Mayo Clinic
- Last updated on ClinicalTrials.gov
- February 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Minnesota · 1
- Mayo Clinic · Rochester, MN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.